Recently, the International Consensus Classification (ICC) and World Health Organization (WHO) classification systems for myelodysplastic syndromes (MDS) were updated and published. Although these two systems are similar, there are key differences which must be taken into consideration by clinicians when diagnosing patients.

In this podcast, experts Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Rami Komrokji, MD, and Somedeb Ball, MD, Moffitt Cancer Center, Tampa, FL, discuss the latest updates in the classification of MDS and share some insights into how these may impact clinical practice.